Toggle Side Panel
Close search

Pulmonary Fibrosis News Community › Forums › Bionews Content › Flash Briefings & Podcasts › PRM-151 Is Slowing Disability Progression Up To 76 Weeks In IPF Patients

  • Flash Briefings & Podcasts

    PRM-151 Is Slowing Disability Progression Up To 76 Weeks In IPF Patients

    Posted by MG Community Member on August 1, 2019 at 2:54 pm

    Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how a study is showing that the investigational therapy PRM-151 is slowing disability progression up to 76 weeks in IPF patients.

    What are your thoughts on this news?

    MG Community Member replied 6 years, 9 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .